[The technologies of genetic engineering in treatment of chronic lower limb ischemia].
The article contains experimental data on angiogenesis stimulated by plasmid containing the angiogenin gene. After the introduction of the gene construction, the number of capillars in the chorion-allantois membrane increases 2 to 3 times; in an ischemized limb of a rat it increases by 20 to 30%. Intramuscular administration of genetic engineering construction to patients with chronic lower limb ischemia improved the patients' condition, consisting in an increase in painless walking distance and ankle-brachial index, as well as in trophic defect healing and the betterment of muscular perfusion. Positive effects were noted after 2 to 4 weeks of treatment and remained during 6 to 24 months. There were no side-effects, except low grade fever during 1 to 2 days.
Bochkov
N P
NP
Konstantinov
B A
BA
Gavrilenko
A V
AV
Voronov
D A
DA
Avdeeva
S V
SV
Khaĭdarova
N V
NV
Tarantul
V Z
VZ
Sverdlov
E D
ED
Naroditskiĭ
B S
BS
Gintsburg
A L
AL
D000256:Adenoviridae / Q000235:genetics; D000328:Adult; D000368:Aged; D000818:Animals; D002642:Chick Embryo; D002908:Chronic Disease; D003627:Data Interpretation, Statistical; D004195:Disease Models, Animal; D005260:Female; D005346:Fibroblast Growth Factors / Q000008:administration & dosage; D005500:Follow-Up Studies; D005818:Genetic Engineering; D005822:Genetic Vectors; D006801:Humans; D007511:Ischemia / Q000628:therapy*; D007866:Leg / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D018919:Neovascularization, Physiologic; D010957:Plasmids / Q000235:genetics; D051381:Rats; D017208:Rats, Wistar; D012259:Ribonuclease, Pancreatic / Q000235:genetics*; D013997:Time Factors; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000008:administration & dosage
D042461:Vascular Endothelial Growth Factor A; D005346:Fibroblast Growth Factors; C046366:angiogenin; D012259:Ribonuclease, Pancreatic